Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
Illinois governor moves to slash cover crop funds despite rising demand
Six years ago, Illinois became the second state in the nation to offer subsidies to farmers... -
Demonstrators protest Trump, Musk in Arlington Heights and other suburbs
Critics of President Donald Trump and adviser Elon Musk took to the streets in Arlington Heights... -
Chicago men accused of trafficking drugs through Lake County
Two Chicago men are facing drug charges following an investigation by a Lake County sheriff’s task...